Quote this publication Share Print

MENVEO and NIMENRIX, meningococcal group A, C, W135 and Y conjugate vaccines

INFECTIOLOGY - Inclusion on list of reimbursable products for supply by pharmacists
Opinions on drugs - Posted on Sep 14 2015

Reason for request

Inclusion

Inclusion on the list of reimbursable products for supply by pharmacists for individuals expected to benefit from long-lasting protection extended to include a larger number of meningococcal serogroups

 

  • MENVEO and NIMENRIX, tetravalent conjugate vaccines, have Marketing Authorisation in active immunisation against invasive meningococcal infections caused by serogroups A, C, W135 and Y from the age of 1 year (NIMENRIX) or 2 years (MENVEO).
  • The need for vaccination against serogroups A, W135 and Y is confined to particular populations: primarily certain research laboratory workers, certain individuals with risk factors for invasive meningococcal infections and individuals travelling to endemic areas, especially pilgrims travelling to Mecca.
  • These vaccines have been available in hospitals and at vaccination centres since 2010 and are now reimbursable for supply by pharmacists only for individuals with risk factors for invasive meningococcal infections who are expected to benefit from long-lasting protection extended to include serogroups A, C, W135 and Y.

Actual benefit

Important

-


Contact Us

Évaluation des médicaments